Poland· PL-100378907

Kimoks

A moxifloxacin product containing moxifloxacinum, registered in Poland by Alkaloid - INT d.o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC J01MA14

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedKimoksATCJ01MA14REGISTER NO.PL-100378907PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Moxifloxacin is registered in 16 of 19 countries.

Countries holding a registration under ATC J01MA14 (moxifloxacin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Moxifloxacin · ATC J01MA14

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of moxifloxacin costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $1.34 in United States to $6.89 in Switzerland — a ×5.2 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Moxifloxacin · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$6.89
  • IT Italy$1.99
  • US United States$1.34 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Moxifloxacinum
Manufacturer
Alkaloid - INT d.o.o.
Country
Poland (PL)
ATC code
J01MA14
ATC class
Moxifloxacin
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991356071
  • gtin
    05909991356088
  • gtin
    05909991356095

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

531 interactions on record for moxifloxacin.

Graded by severity as the source publishes them — 175 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Moxifloxacin · interactions on record

531 records

  • 175 severe
  • 140 moderate
  • 49 minor
  • 92 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe

75 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Moxifloxacin in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All moxifloxacin products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Avelox, Moxifloxacin 1a Pharma
  • Belgium · Avelox, Kanavig
  • Bulgaria · Cimocinox, Moxifloxacin Kabi
  • Cyprus · Avelox, Erelan
  • Czechia · Avelox, Moxifloxacin Brown & Burk
  • Germany · Avalox, Moxifloxacin 1 A Pharma
  • Denmark · Moxifloxacin Accord, Moxifloxacin Fresenius Kabi
  • Estonia · Avelox, Floxelan
  • Spain · Abimox, Actira
  • Finland · Moxifloxacin Fresenius Kabi, Moxifloxacin Krka
  • France · Izilox, Moxifloxacine Arrow
  • United Kingdom (Northern Ireland) · Avelox, Moxidox
  • Greece · Avelox, Mikrobiel
  • Croatia · Melvedok, Moksacin 5 Mg/Ml Kapi
  • Hungary · Moxibiot, Moxifloxacin Anfarm
  • Ireland · Moxifloxacin
  • Iceland · Vigamox
  • Italy · Avalox, Moxidrop
  • Lithuania · Avelox, Ekara
  • Luxembourg · Avelox, Kanavig
  • Latvia · Avelox, Ekara
  • Malta · Erelan, Moxifloxacin Anfarm
  • Netherlands · Erelan, Moxifloxacin Hydrochloride Aurobindo
  • Norway · Xinaflox
  • Portugal · Avelox, Bluesar
  • Romania · Avelox, Kimoks
  • Sweden · Moxifloxacin Fresenius Kabi, Moxifloxacin Krka
  • Slovenia · Kimoks, Moksifloksacin Kabi
  • Slovakia · Avelox, Moloxin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a077f811-6ece-43b2-a657-07722d8de603
GET /v1/drugs/a077f811-6ece-43b2-a657-07722d8de603?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "05909991356071 ¦ Rp ¦ 125721\n5 tabl.\n05909991356088 ¦ Rp ¦ 125722\n7 tabl.\n05909991356095 ¦ Rp ¦ 125723\n10 tabl.",
  "substance": "Moxifloxacinum 400 mg",
  "common_name": "Moxifloxacinum",
  "pl_product_id": "100378907",
  "pozwolenie_nr": "24442",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}

See everything about moxifloxacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.